Clinical Trials Using LMP1/BARF1/EBNA1-specific Cytotoxic T-lymphocytes

Clinical trials are research studies that involve people. The clinical trials on this list are studying LMP1/BARF1/EBNA1-specific Cytotoxic T-lymphocytes. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • LMP1 / BARF1 / EBNA1-Specific Cytotoxic T-Lymphocytes with or without Cyclophosphamide and Fludarabine in Treating Participants with EBV-Positive Lymphoma

    This phase I trial studies the side effects and best dose of LMP1 / BARF1 / EBNA1-specific cytotoxic T-lymphocytes when given together with or without cyclophosphamide and fludarabine in treating participants with Epstein-Barr virus (EBV)-positive lymphoma. Immunotoxins, such as LMP1 / BARF1 / EBNA1-specific cytotoxic T-lymphocytes, are antibodies linked to a toxic substance and may help find certain cancer cells and kill them without harming normal cells. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving LMP1 / BARF1 / EBNA1-specific cytotoxic T-lymphocytes, cyclophosphamide, and fludarabine together may work better in treating participants with EBV-positive lymphoma.
    Location: 3 locations